

Urological Cancer Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/U6D7F5912D6MEN.html>

Date: April 2018

Pages: 144

Price: US\$ 3,480.00 (Single User License)

ID: U6D7F5912D6MEN

Abstracts

Report Summary

Urological Cancer Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023

Main market players of Urological Cancer Drugs in United States, with company and product introduction, position in the Urological Cancer Drugs market

Market status and development trend of Urological Cancer Drugs by types and applications

Cost and profit status of Urological Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Urological Cancer Drugs market as:

United States Urological Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Urological Cancer Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

United States Urological Cancer Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

United States Urological Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.
Tolmar Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS

- 1.1 Definition of Urological Cancer Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Drugs
 - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.2 Jevtana (Cabazitaxel)
 - 1.2.3 Inlyta (Axitinib)
 - 1.2.4 Votrient (Pazopanib Hydrochloride)
 - 1.2.5 Sutent (Sunitinib Malate)
 - 1.2.6 Zytiga (Abiraterone Acetate)
 - 1.2.7 Xtandi (Enzalutamide)
 - 1.2.8 Opdivo (Nivolumab)
 - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Drugs
 - 1.3.1 Prostate Cancer
 - 1.3.2 Bladder Cancer
 - 1.3.3 Kidney Cancer
 - 1.3.4 Testicular Cancer
- 1.4 Development History of Urological Cancer Drugs
- 1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
 - 1.5.1 United States Urological Cancer Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Urological Cancer Drugs in United States 2013-2017
- 2.2 Consumption Market of Urological Cancer Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Urological Cancer Drugs in United States by Regions
 - 2.2.2 Revenue of Urological Cancer Drugs in United States by Regions
- 2.3 Market Analysis of Urological Cancer Drugs in United States by Regions
 - 2.3.1 Market Analysis of Urological Cancer Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Urological Cancer Drugs in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Urological Cancer Drugs in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Urological Cancer Drugs in The West 2013-2017
 - 2.3.5 Market Analysis of Urological Cancer Drugs in The South 2013-2017
 - 2.3.6 Market Analysis of Urological Cancer Drugs in Southwest 2013-2017
- 2.4 Market Development Forecast of Urological Cancer Drugs in United States

2018-2023

2.4.1 Market Development Forecast of Urological Cancer Drugs in United States

2018-2023

2.4.2 Market Development Forecast of Urological Cancer Drugs by Regions

2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Urological Cancer Drugs in United States by Types

3.1.2 Revenue of Urological Cancer Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Urological Cancer Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Urological Cancer Drugs in United States by Downstream Industry

4.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Urological Cancer Drugs by Downstream Industry in New England

4.2.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Urological Cancer Drugs by Downstream Industry in The Midwest

4.2.4 Demand Volume of Urological Cancer Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Urological Cancer Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Urological Cancer Drugs by Downstream Industry in Southwest

4.3 Market Forecast of Urological Cancer Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Urological Cancer Drugs in United States by Major Players

6.2 Revenue of Urological Cancer Drugs in United States by Major Players

6.3 Basic Information of Urological Cancer Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Players

6.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Novartis

7.1.1 Company profile

7.1.2 Representative Urological Cancer Drugs Product

7.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.2 Pfizer

7.2.1 Company profile

7.2.2 Representative Urological Cancer Drugs Product

7.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.3 Johnson & Johnson

7.3.1 Company profile

7.3.2 Representative Urological Cancer Drugs Product

7.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.4 AstraZeneca

7.4.1 Company profile

7.4.2 Representative Urological Cancer Drugs Product

7.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

7.5 Astellas

7.5.1 Company profile

7.5.2 Representative Urological Cancer Drugs Product

7.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas

7.6 Bristol-Myers Squibb

7.6.1 Company profile

7.6.2 Representative Urological Cancer Drugs Product

7.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.7 Abbott Laboratories

7.7.1 Company profile

7.7.2 Representative Urological Cancer Drugs Product

7.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.8 Celgene Corporation

7.8.1 Company profile

7.8.2 Representative Urological Cancer Drugs Product

7.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation

7.9 Dendreon Corporation

7.9.1 Company profile

7.9.2 Representative Urological Cancer Drugs Product

7.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation

7.10 Ferring Pharmaceuticals

7.10.1 Company profile

7.10.2 Representative Urological Cancer Drugs Product

7.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals

7.11 GlaxoSmithKline

7.11.1 Company profile

7.11.2 Representative Urological Cancer Drugs Product

7.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.12 Indevus Pharmaceuticals Inc

7.12.1 Company profile

7.12.2 Representative Urological Cancer Drugs Product

7.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc

7.13 Ipsen

7.13.1 Company profile

7.13.2 Representative Urological Cancer Drugs Product

7.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen

7.14 Roche Healthcare

7.14.1 Company profile

7.14.2 Representative Urological Cancer Drugs Product

7.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare

7.15 Sanofi S.A.

7.15.1 Company profile

7.15.2 Representative Urological Cancer Drugs Product

7.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

7.16 Tolmar Inc

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS

8.1 Industry Chain of Urological Cancer Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS

9.1 Cost Structure Analysis of Urological Cancer Drugs

9.2 Raw Materials Cost Analysis of Urological Cancer Drugs

9.3 Labor Cost Analysis of Urological Cancer Drugs

9.4 Manufacturing Expenses Analysis of Urological Cancer Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Urological Cancer Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/U6D7F5912D6MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U6D7F5912D6MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970